Susan Hasty, Publisher
Table of Contents . . . September 27th, 1999Non-Subscriber - Summaries Only
At-Risk Populations (HCV) - Quasispecies Change May Explain Poor Response to IFN
Drug Resistance - Model for Lamivudine Resistance Revealed
Drug Resistance - Natural Protein Pumps Nucleoside Analogs Out of Cells
Interferon Therapy - TNF-I Is Marker of Interferon Administration
Interferon Therapy (HBV) - Patients with Hepatitis B Benefit from IFN
Interferon Therapy (HCV) - Patients with Thyroid Autoantibodies Are Candidates for IFN
Transmission (HCV) - Blood Recipients in India Still Face HCV Risk
Bone Marrow Transplantation (HGV Infection) - Impact of HGV on BMT Recipients Evaluated
Drug Development - 2,6-Diaminopurine Z-Prodrug Has Antiviral Properties
Epidemiology (HCV) - New Jersey Now Requiring Reports of All Hepatitis C Cases
Industry News (Funding) - Boston Biomedica Awarded Three NIH SBIR Grants
Testing (ALT) - Clearance Announced for ALT Test
Therapeutic Indicators - Viral RNA Persistence in PBMCs Point to Treatment Failure
Combination Therapy (Adverse Events) - "Unilateral Loss of Vision Associated with Intron A and Ribavirin Combination Therapy for Chronic Hepatitis C: Report of a Case."
Combination Therapy (HCV) - "Effects of Combined Intron-A/Ribavirin Therapy on Previously Untreated Chronic Hepatitis C Patients."
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.